Cardiff Oncology has been granted a patent for a method to treat lung or gastric cancer by administering FGFR inhibitor and onvansertib to inhibit cancer progression. The method involves a combination of specific inhibitors to effectively target and treat the cancer in subjects. GlobalData’s report on Cardiff Oncology gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Cardiff Oncology, Personalized medicine biomarkers was a key innovation area identified from patents. Cardiff Oncology's grant share as of May 2024 was 41%. Grant share is based on the ratio of number of grants to total number of patents.
Combination treatment for lung and gastric cancer
A recently granted patent (Publication Number: US11957677B2) discloses a method for therapeutically treating lung cancer or gastric cancer by administering a fibroblast growth factor receptor (FGFR) inhibitor and onvansertib to inhibit the progression of the cancer. The method involves identifying subjects with FGFR-amplified cancer or cancer with FGFR overexpression and administering the combination treatment to them. The patent claims that the inhibition of cancer progression achieved with the combination treatment is greater than that achieved by either treatment alone.
Furthermore, the patent also covers a method for sensitizing lung cancer or gastric cancer cells to an FGFR inhibitor by contacting the cancer cells with a composition containing onvansertib. This method can be carried out in vitro, ex vivo, or in vivo, and aims to enhance the effectiveness of the FGFR inhibitor in treating the cancer cells. The patent includes claims related to determining the sensitization of cancer cells to the FGFR inhibitor after contact with the composition, as well as the direct contact of cancer cells with the FGFR inhibitor in the sensitization process.
To know more about GlobalData’s detailed insights on Cardiff Oncology, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
